Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy

Falk M, et al. Response of an HER2-Mutated NSCLC Patient to Trastuzumab Deruxtecan and Monitoring of Plasma ctDNA Levels by Liquid Biopsy. Curr Oncol 2023 Jan 30;30(2):1692-1698. doi:10.3390/curroncol30020130

Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica

Mahjoubi L, Cecchi F, Massard C, Calabro F, Gazzah A, Bahleda R, et al. Personalized therapy based on sequential molecular analysis leads to 30 months of survival in a patient with diffuse unresectable gastric linitis plastica. Tumori 2018 Dec;104(6):NP38-NP41. doi: 10.1177/0300891618763215